Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib as Perioperative Therapy in Resectable EGFR+ Lung Adenocarcinoma (FRONT)
NCT04965831Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of furmonertinib in lung adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT04965831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965831.